Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M.

ALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...

The first four treatments in a platform trial for amyotrophic lateral sclerosis (ALS) failed to reach key endpoints in phase ...

Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ...

Four papers published in JAMA, JAMA Neurology and JAMA Network Open look at Amyotrophic Lateral Sclerosis (ALS) treatment results from the HEALY ALS Platform Trial. Dr Ahmad Al Khleifat, Senior ...

Of the first four experimental ALS treatments tested in the HEALEY platform trial, CNM-Au8 and pridopridine showed some promising results.

Denali Therapeutics' experimental drug for amyotrophic lateral sclerosis (ALS) failed to show efficacy in part of the phase 2/3 HEALEY ALS basket trial, causing a fall in its share price.

Broking analysts have lowered their expectations on Cochlear (ASX:COH), but in the main their valuations are above the ...

A new study published in the recent issue of Journal of American Medical Association found that the usage of verdiperstat, a ...